# A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

> **NCT06248814** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 64 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** BMS-986326
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06248814
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-06
- **Primary completion:** 2025-11-06
- **Final completion:** 2025-11-06
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06248814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06248814, "A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06248814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*